IOVA
Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc.IOVA

Healthcare · Biotechnology
14.58USD
+5.81%
Oct 28, 2026
IOVA overview ready
Commercial-stage developer and manufacturer of autologous tumor-infiltrating-lymphocyte therapy for solid tumors.
Narrative is still early
Exposed to the Cell Therapy Expansion Into Solid Tumors narrative through Adoptive Cell Therapy Commercialization in Solid Tumors — pure play.
Constructive pullback in an uptrend
Longer-term context reads extended trend, with a near-term setup of extended daily.
Demanding valuation
The price embeds expectations that run ahead of the cash the business currently produces.
Fundamentals under pressure
Ev / sales is weak.
Primary risk
Regulatory approval delays or failures.
Market Oct 27Price action Oct 23Research Oct 23

Conviction Level

CompanyFit8.0PriceAction5.1Valuation0.3CompanyPosition9.3BusinessQuality—

Conviction uses Company Fit, Price Action, Valuation, Business Quality. Company Position is research context, not an input.

Theme leadershipGroup context · not a Conviction input
Cell Therapy has only one or two eligible stocks — no leadership reading
Price
Loading price history…

Price Action

Constructive pullback in an uptrend
Longer-term context reads extended trend, with a near-term setup of extended daily.
EntryBreakout + retest

Price broke through the weekly SMA200, then retested it constructively and recovered — a fresh structural entry rather than a chase.

Key Financials

Market Cap
$6.4B
Avg Volume (60D)
14.7M
60 sessions
Revenue Growth YoY
+34.5%
Trailing twelve months
Gross Margin
+48.4%
Operating Margin
-91.2%
Trailing twelve months
Free Cash Flow Yield
-2.9%
EV / Sales
18.9x
Market metrics as of Oct 27, 2026

Fundamentals & Valuation

Both valuation perspectives agree this company is expensive.
This company has an Expensive valuation stance because the price embeds expectations that run ahead of the cash the business currently produces.

Company Research

Thesis
Commercial-stage developer and manufacturer of autologous tumor-infiltrating-lymphocyte therapy for solid tumors. IOVA is a direct, commercially exposed participant in the emerging solid-tumor cell-therapy adoption cycle rather than a generic oncology adjacency.
Opportunity
Moderate opportunity
Regulatory validation, treatment-center adoption, reimbursement, and specialized manufacturing are expanding the use of personalized cellular immunotherapies beyond hematologic cancers into solid-tumor indications.
Key risk
Regulatory approval delays or failures.

Economic classification

Loading the economic classification…

Business & Markets

Healthcare · Biotechnology
What they do

Iovance Biotherapeutics develops and commercializes autologous tumor infiltrating lymphocyte cell therapies for treating metastatic melanoma and other solid tumors in the U.S. Internationally.

How it earns

The company generates revenue through the sale of its cell therapy products to healthcare providers treating eligible cancer patients.

Products & services
Amtagvi (individualized T cell therapy for solid tumors)
Proleukin (interleukin-2 treatment for metastatic melanoma and renal cell carcinoma)
Customers & end markets
Oncology healthcare providers
Patients with metastatic melanoma and other solid tumors
Market position

Niche player focused on autologous cell therapies for solid tumors within the biotechnology sector.

Demand drivers
Medium cyclicality

Demand depends on cancer treatment cycles and regulatory approvals but is less sensitive to economic cycles.